Eli Lilly vs Novo Nordisk: The 1 Figure Investors Shouldn't Ignore

Over the past few years, Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have been dominating one of the biggest growth markets in the pharma industry: the weight loss drug market. Demand for these drugs has soared -- even resulting in product shortages at times -- and analysts expect the market to reach nearly $100 billion by 2030.Novo was first to market with semaglutide, commercialized as Ozempic for type 2 diabetes and Wegovy for weight loss. Lilly then joined the market with tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for weight loss. Both are part of the class of drugs known as GLP-1, a type of product that acts on hormones involved in blood sugar and appetite management.Now, as we consider these two rivals, there's one figure investors shouldn't ignore. Let's check it out.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool